Phosphodiesterase 9 (PDE9) Inhibitor
IMR-687 for Sickle Cell Disease
Recruiting1 awardPhase 2
Farmington, Connecticut
This trial is testing IMR-687, a medication, in adult patients with Sickle Cell Anemia who were in a previous study. It aims to see if the medication is safe and well-tolerated by monitoring side effects and body responses.
Histone Deacetylase Inhibitor
Panobinostat for Sickle Cell Disease
Recruiting3 awardsPhase 1
Augusta, Georgia
This trial is testing a drug called panobinostat to see if it is safe and effective in treating adults with sickle cell disease. Panobinostat is a pan histone deacetylase (HDAC) inhibitor, which has been shown to increase hemoglobin F induction and inhibit cell-specific inflammation.
Popular Filters
Trials for Sickle Cell Disease Patients
Behavioral Intervention
Gerofit Exercise for Sickle Cell Disease
Recruiting1 award2 criteria
Durham, North Carolina
This trial is testing a personalized exercise program for adults aged 40 and older with sickle cell disease. The goal is to see if this exercise plan can improve their physical health and quality of life. Participants will be monitored regularly to track their progress and provide feedback on the program. Exercise programs have been studied as a potential therapeutic strategy for patients with sickle cell disease, showing benefits in functional capacity and cardiovascular health.
Small Molecule
Etavopivat for Sickle Cell Disease
Recruiting1 awardPhase 2
Whittier, California
This trial is testing a new oral medicine called etavopivat in patients with sickle cell disease or thalassemia. The medicine helps red blood cells produce energy more efficiently. The goal is to reduce the need for blood transfusions and increase hemoglobin levels.
Carbon Dioxide for Sickle Cell Anemia
Recruiting1 award10 criteria
Saint Louis, Missouri
This trial is looking at how blood flow and metabolism affects brain development in early life. SCA participants and healthy controls will have their blood flow and metabolism examined using MRI, and will also undergo cognitive assessments and brief questionnaires.
Trials for SCD Patients
Behavioral Intervention
Gerofit Exercise for Sickle Cell Disease
Recruiting1 award2 criteria
Durham, North Carolina
This trial is testing a personalized exercise program for adults aged 40 and older with sickle cell disease. The goal is to see if this exercise plan can improve their physical health and quality of life. Participants will be monitored regularly to track their progress and provide feedback on the program. Exercise programs have been studied as a potential therapeutic strategy for patients with sickle cell disease, showing benefits in functional capacity and cardiovascular health.
Small Molecule
Etavopivat for Sickle Cell Disease
Recruiting1 awardPhase 2
Whittier, California
This trial is testing a new oral medicine called etavopivat in patients with sickle cell disease or thalassemia. The medicine helps red blood cells produce energy more efficiently. The goal is to reduce the need for blood transfusions and increase hemoglobin levels.
Carbon Dioxide for Sickle Cell Anemia
Recruiting1 award10 criteria
Saint Louis, Missouri
This trial is looking at how blood flow and metabolism affects brain development in early life. SCA participants and healthy controls will have their blood flow and metabolism examined using MRI, and will also undergo cognitive assessments and brief questionnaires.
Trials With No Placebo
Behavioral Intervention
Gerofit Exercise for Sickle Cell Disease
Recruiting1 award2 criteria
Durham, North Carolina
This trial is testing a personalized exercise program for adults aged 40 and older with sickle cell disease. The goal is to see if this exercise plan can improve their physical health and quality of life. Participants will be monitored regularly to track their progress and provide feedback on the program. Exercise programs have been studied as a potential therapeutic strategy for patients with sickle cell disease, showing benefits in functional capacity and cardiovascular health.
Small Molecule
Etavopivat for Sickle Cell Disease
Recruiting1 awardPhase 2
Whittier, California
This trial is testing a new oral medicine called etavopivat in patients with sickle cell disease or thalassemia. The medicine helps red blood cells produce energy more efficiently. The goal is to reduce the need for blood transfusions and increase hemoglobin levels.
Carbon Dioxide for Sickle Cell Anemia
Recruiting1 award10 criteria
Saint Louis, Missouri
This trial is looking at how blood flow and metabolism affects brain development in early life. SCA participants and healthy controls will have their blood flow and metabolism examined using MRI, and will also undergo cognitive assessments and brief questionnaires.
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.